ReviewApplied microbiology and biotechnology2015
Sustainable source of omega-3 eicosapentaenoic acid from metabolically engineered Yarrowia lipolytica: from fundamental research to commercial production.
Review in Applied microbiology and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 225 citations in OpenAlex.
- Marine Microalgal Genes: Unlocking a New Era of Sustainable High Value PUFA Production for Neuroprotective Applications.Cell biochemistry and biophysics · 2026Review
- Biosynthesis of Sciadonic Acid Derived from Gymnosperms with Anti-Colitis Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
- Lipid accumulation in nitrogen and phosphorus-limited yeast is caused by less growth-related dilution.Metabolic engineering · 2026Article
- A workflow to explore elongase diversity and extend the repertoire of fatty acids produced by Yarrowia lipolytica.Microbial cell factories · 2025Article
- Article
- Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults.International journal of molecular sciences · 2025Article
- A Review on Marine Microbial Docosahexaenoic Acid Production Through Circular Economy, Fermentation Engineering, and Antioxidant Technology.Marine drugs · 2025Review
- An engineeredSynthetic and systems biotechnology · 2025Article
- Engineering yeast for tailored fatty acid profiles.Applied microbiology and biotechnology · 2025Review
- Metabolic Engineering ofACS engineering Au · 2025Article
- Establishment of CRISPR-STAR System to Realise Simultaneous Transcriptional Activation and Repression in Yarrowia lipolytica.Microbial biotechnology · 2025Article
- Effect of sheep placenta extract on D-galactose-induced aging mouse.Frontiers in pharmacology · 2025Article
- Cell-cultivated aquatic food products: emerging production systems for seafood.Journal of biological engineering · 2024Review
- Chemical Characterisation of New Oils Extracted from Cañihua and Tarwi Seeds with Different Organic Solvents.Foods (Basel, Switzerland) · 2024Article
- Factors impacting the microbial production of eicosapentaenoic acid.Applied microbiology and biotechnology · 2024Review
- Oleaginous Microbial Lipids' Potential in the Prevention and Treatment of Neurological Disorders.Marine drugs · 2024Review
- High-level production of nervonic acid in the oleaginous yeast Yarrowia lipolytica by systematic metabolic engineering.Communications biology · 2023Article
- Biomanufacturing of γ-linolenic acid-enriched galactosyldiacylglycerols: Challenges in microalgae and potential in oleaginous yeasts.Synthetic and systems biotechnology · 2023Review
- Microbial production of nutraceuticals: Metabolic engineering interventions in phenolic compounds, poly unsaturated fatty acids and carotenoids synthesis.Journal of food science and technology · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The omega-3 fatty acids, cis-5, 8, 11, 14, and 17-eicosapentaenoic acid (C20:5; EPA) and cis-4, 7, 10, 13, 16, and 19-docosahexaenoic acid (C22:6; DHA), have wide-ranging benefits in improving heart health, immune function, mental health, and infant cognitive development. Currently, the major source for EPA and DHA is from fish oil, and a minor source of DHA is from microalgae. With the increased demand for EPA and DHA, DuPont has developed a clean and sustainable source of the omega-3 fatty acid EPA through fermentation using metabolically engineered strains of Yarrowia lipolytica. In this mini-review, we will focus on DuPont's technology for EPA production. Specifically, EPA biosynthetic and supporting pathways have been introduced into the oleaginous yeast to synthesize and accumulate EPA under fermentation conditions. This Yarrowia platform can also produce tailored omega-3 (EPA, DHA) and/or omega-6 (ARA, GLA) fatty acid mixtures in the cellular lipid profiles. Fundamental research such as metabolic engineering for strain construction, high-throughput screening for strain selection, fermentation process development, and process scale-up were all needed to achieve the high levels of EPA titer, rate, and yield required for commercial application. Here, we summarize how we have combined the fundamental bioscience and the industrial engineering skills to achieve large-scale production of Yarrowia biomass containing high amounts of EPA, which led to two commercial products, New Harvest™ EPA oil and Verlasso® salmon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.